APYX
Apyx Medical Corporation
NASDAQ · Healthcare · Medical - Devices · US
$3.05
−0.33%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 58.4M | 52.8M | 48.1M | 52.3M | 44.5M |
| Cost of Revenue | 38.6M | 33.8M | 18.7M | 18.6M | 15.4M |
| Gross Profit | 19.8M | 19.0M | 29.4M | 33.8M | 29.1M |
| Operating Expenses | |||||
| R&D Expense | 3.3M | 3.4M | 5.1M | 4.8M | 4.5M |
| SG&A Expense | 28.2M | 36.1M | 43.1M | 48.9M | 48.1M |
| General & Admin Expense | 12.5M | 36.1M | 43.1M | 48.9M | 48.1M |
| Selling & Marketing Expense | 6.8M | — | — | — | — |
| Other Expenses | (8.2M) | (14.0M) | — | (2.7M) | — |
| Total Operating Expenses | 23.4M | 25.5M | 48.2M | 51.0M | 52.7M |
| Cost and Expenses | 62.0M | 59.3M | 66.9M | 69.6M | 68.1M |
| Operating Income (EBIT) | (3.5M) | (6.4M) | (18.8M) | (17.3M) | (23.6M) |
| Non-Operating | |||||
| Interest Income | 1.0M | 1.1M | 1.6M | 921.0K | 157.0K |
| Interest Expense | 5.6M | 5.6M | 5.9M | 2.5M | 15.0K |
| Net Interest Income | (4.6M) | (4.5M) | (4.3M) | (1.6M) | 142.0K |
| Other Non-Op Income/Expense | (4.4M) | (4.4M) | (4.5M) | (4.0M) | 651.0K |
| Non-Operating Income (excl Interest) | (1.1M) | (1.2M) | (1.4M) | 1.5M | (666.0K) |
| EBT (Pre-Tax Income) | (8.0M) | (10.8M) | (23.3M) | (21.3M) | (22.9M) |
| Income Tax Expense | 439.0K | 270.0K | 252.0K | (2.4M) | 367.0K |
| Bottom Line | |||||
| Net Income | (8.6M) | (11.2M) | (23.5M) | (18.7M) | (23.2M) |
| Earnings from Cont. Ops | (8.4M) | (11.1M) | (23.6M) | (18.9M) | (23.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (8.6M) | (11.2M) | (23.5M) | (18.7M) | (23.2M) |
| Per Share | |||||
| Basic EPS | ($0.21) | ($0.27) | ($0.66) | ($0.54) | ($0.67) |
| Diluted EPS | ($0.21) | ($0.27) | ($0.66) | ($0.54) | ($0.67) |
| Revenue Per Share | $1.39 | $1.25 | $1.35 | $1.51 | $1.29 |
| Shares | |||||
| Basic Shares Outstanding | 42.2M | 42.2M | 35.5M | 34.6M | 34.5M |
| Diluted Shares Outstanding | 42.2M | 42.2M | 35.5M | 34.6M | 34.5M |
| Profitability Metrics | |||||
| EBITDA | (1.6M) | (4.6M) | (16.8M) | (18.1M) | (22.0M) |
| D&A | 751.0K | 655.0K | 599.0K | 692.0K | 890.0K |
| EBIT | (2.4M) | (5.2M) | (17.4M) | (18.8M) | (22.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026